Director, Document Control

Associate Scientist I, Analytical Development

Group Leader, Formulation Development

Director, Analytical Development

Sr. Manager, Clinical Supply

Director, Clinical Supply

Document Control Specialist

Associate Scientist II, Polysaccharide Process Development

Manager/ Sr. Manager, Equity Administration

Head of CMC IT Systems

Sr. Regulatory Document Formatting Specialist

Engineer II, Drug Product Engineering

Sr. Associate Scientist, Downstream Development for Protein Development & Manufacturing

Stability Manager

Associate Scientist I, Protein Process Development & Manufacturing

Manager, Employee Programs

Sr. Associate Scientist, Conjugation Development

Sr. Associate Engineer, Polysaccharide Pilot Plant

Associate Director, Conjugation Development & Clinical Manufacturing

Sr. Paralegal

Scientist II, Formulation Development

Associate Director of Accounting, Clinical Trials & Shared Services

Sr. Accounting Manager, Manufacturing

Associate Director/ Director, Formulation Development

Scientist I, Conjugation Development

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Ascidian Therapeutics

Ascribe Bioscience

Asher Biotherapeutics

Asimov

Vaxcyte is creating therapeutic vaccines to eliminate bacterial infections. Bacterial infections remain one of the greatest public health challenges, including infections caused by pneumococcal disease and periodontitis. Many emerging serotypes of pneumococcal disease are not covered by current vaccines. Vaxcyte aims to fix this problem by using their chemistry and cell-free protein synthesis platform (XpressCF) to engineer more effective vaccines. The valency of the vaccines is enhanced to offer precise, site-specific conjugation to immune epitopes. Vaxcyte’s lead candidate, VAX-24, is in Phase 2 clinical trials to be later used for pneumococcal disease with 3 other candidates in earlier stage development.  

<p>Vaxcyte is creating therapeutic vaccines to eliminate bacterial infections. Bacterial infections remain one of the greatest public health challenges, including infections caused by pneumococcal disease and periodontitis. Many emerging serotypes of pneumococcal disease are not covered by current vaccines. Vaxcyte aims to fix this problem by using their chemistry and cell-free protein synthesis platform (XpressCF) to engineer more effective vaccines. The valency of the vaccines is enhanced to offer precise, site-specific conjugation to immune epitopes. Vaxcyte’s lead candidate, VAX-24, is in Phase 2 clinical trials to be later used for pneumococcal disease with 3 other candidates in earlier stage development.  </p>


Vaxcyte

Find a biotech startup job.